In this study, we used mithramycin A (MMA), an FDA-approved chemotherapeutic agent that competitively blocks the binding of SP1 to gene promoters, to demonstrate that combination treatment with an SP1 inhibitor and a YAP/TEAD inhibitor could improve antitumor activity in CRC. Here, SP1 is linked to colorectal carcinoma.